| For: | Peng XD, You ZY, He LX, Deng Q. Zimberelimab plus chemotherapy as the first-line treatment of malignant peritoneal mesothelioma: A case report and review of literature. World J Clin Cases 2023; 11(22): 5296-5302 [PMID: 37621601 DOI: 10.12998/wjcc.v11.i22.5296] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v11/i22/5296.htm |
| Number | Citing Articles |
| 1 |
Mitchell Emmers, Danielle de Graaf-Wuite, Cornelis Verhoef, Joachim G J V Aerts, Eva V E Madsen. Usage of immune checkpoint blockade in peritoneal mesothelioma: a systematic review of the literature. BMJ Connections Oncology 2025; 2(1): e000039 doi: 10.1136/bmjconc-2025-000039
|
| 2 |
Cisplatin/pemetrexed/zimberelimab. Reactions Weekly 2023; 1976(1): 107 doi: 10.1007/s40278-023-46836-y
|
| 3 |
M. Lizeth Orozco Morales, Sally M. Lansley, Wee Loong Chin, Caitlin M. Tilsed, Nicola Principe, Connull Leslie, Breana J. Vitali, Francois X. Rwandamuriye, Emma de Jong, Joel Kidman, Rachael M. Zemek, Catherine A. Rinaldi, Timo Lassmann, Anthony Bosco, Y. C. Gary Lee, Richard A. Lake, Jonathan Chee, W. Joost Lesterhuis. Mesothelioma location influences the tumour microenvironment and immune checkpoint therapy response in preclinical models. Scientific Reports 2026; doi: 10.1038/s41598-026-41431-4
|
